Skip to content
Peptide research

Suprefort

Also known as Pancreas Bioregulator
Category
Bioregulators
Administration routes
Oral
Regulatory status
Not FDA-approved

Suprefort is a bioregulator peptide from pancreatic tissue, marketed to support pancreatic function in aging. Its best claim, glucose stabilization in early diabetes, rests on weak human data; digestive claims have limited observational support, while normalization of pancreatic function remains unproven. Main risks are a low chance of allergic reaction (bovine origin) and interaction with diabetes medications. It is not FDA-approved, and available products are unregulated.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Suprefort is a natural peptide bioregulator containing a complex of low-molecular-weight peptides (up to 10,000 Da) extracted from the pancreas of young calves. Developed by Professor Vladimir Khavinson, it belongs to the Cytomaxes class and targets pancreatic tissue, where it is designed to restore metabolism and normalize the functional activity of both the exocrine (digestive enzyme) and endocrine (insulin) functions of the pancreas.

Clinical studies at the St. Petersburg Institute tested Suprefort in 34 patients with chronic pancreatitis (latent form, n=12) and type 2 diabetes mellitus (latent form, n=22). Patients with pancreatitis showed increased appetite, decreased dyspeptic symptoms, and stabilized stool. Patients with type 2 diabetes showed a tendency toward glucose level normalization. The study used matched controls receiving standard therapy alone and demonstrated add-on benefit for Suprefort over 15 days of treatment.

Suprefort is particularly positioned within the broader context of Khavinson's research on peptide regulation of aging, as pancreatic function decline is a hallmark of metabolic aging. Khavinson's bioregulator theory holds that short signaling peptides induce protein synthesis through complementary interaction with DNA-specific binding sites, and how long-term application can lead to lifespan increases of 20-40% in animal models.

How it works in the body

A bioregulator peptide complex derived from pancreatic tissue. It targets pancreatic acinar and islet cells to regulate gene expression involved in digestive enzyme production and insulin signaling, supporting pancreatic function during aging.

Research overview

Suprefort has a formal clinical study from the Khavinson Institute testing 34 patients (12 with chronic pancreatitis, 22 with latent type 2 diabetes) against matched controls. Results showed improvement in digestive symptoms for pancreatitis patients and glucose stabilization trends in diabetes patients. The study was conducted from November 2003 to January 2004. Additionally, the broader Khavinson research program provides mechanistic context for how pancreatic peptides regulate gene expression and protein synthesis. Suprefort is also related to Pancragen, the synthetic Cytogen counterpart. No independent Western clinical trials exist.

Who researches Suprefort?

Commonly researched by

  • People researching GI and digestive health

    Studied for gastrointestinal protection, gut lining repair, or digestive support.

  • People researching longevity and anti-aging interventions

    Studied for effects on aging pathways, cellular health, or lifespan extension.

  • People researching blood sugar regulation

    Studied for effects on insulin sensitivity, glucose metabolism, or glycemic control.

Important considerations for

  • Those who are pregnant or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Anyone under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Those with Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Safety & interactions

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(2)

Rated by level of concern

  • Allergic reaction to bovine pancreas-derived peptides

    Low

    Class inference from animal-derived pancreatic products (e.g. pancrelipase prescribing information); no Suprefort-specific case reports found on PubMed

  • Potential interaction with diabetes medications

    Moderate

    Potential interaction is theoretical; no Suprefort-specific interaction study was identified. PMIDs 22448364 and 28976155 concern Pancragen/pankragen-forte, not Suprefort.

Interaction summary(7)

Rated by direction with this peptide

  • Insulin (all formulations)

    CautionModerate

    Human open-label data with the pancreatic tetrapeptide (not the Suprefort extract) show reduced fasting glucose, OGTT glucose and plasma insulin/insulin resistance in elderly subjects, so added glucose lowering on a fixed insulin dose could in principle precipitate hypoglycemia without dose review and glucose monitoring. No co-administration study exists and no hypoglycemia was reported in the source trials.

    PMID 22448364 (glycemic effect in humans); no insulin co-administration study identified

  • Sulfonylureas and glinides (glipizide, glyburide, glimepiride, repaglinide)

    CautionModerate

    Mechanism-based, not studied in humans: these agents force insulin secretion independent of glucose, so any additional glucose-lowering effect would add to that of the highest-hypoglycemia-risk oral class. The only head-to-head data are in old rhesus monkeys, where pancragen and glimepiride were compared as alternatives rather than combined.

    PMID 28509500 (pancragen vs glimepiride comparison, monkeys, not combination); otherwise mechanism-based secretagogue pharmacology

  • Metformin

    CautionLow

    Additive glycemic effect is plausible and would usually be desirable, and metformin alone rarely causes hypoglycemia, so the practical concern is drifting below target rather than an acute event. No co-administration data exist.

    Mechanism-based; human glycemic data PMID 22448364

  • GLP-1 receptor agonists and DPP-4 inhibitors

    SynergisticTheoretical

    Both act on beta-cell function, and pancragen is proposed to support islet cells via differentiation and gene-expression effects, so combined benefit is mechanistically plausible. This has never been tested in any published study, and no published data link pancragen to the incretin axis specifically.

    Mechanism only; in vitro islet differentiation data PMID 23486591

  • Systemic corticosteroids (prednisone, dexamethasone)

    CautionTheoretical

    Steroid-induced insulin resistance and hyperglycemia would be expected to blunt or cancel any glycemic benefit, and could mask a real loss of control if the peptide is credited for stability.

    Mechanism-based (well-established steroid hyperglycemia); no interaction study exists

  • Antiplatelet and anticoagulant therapy (aspirin, clopidogrel, DOACs)

    CautionTheoretical

    The pankragen-forte prediabetes study reported reduced platelet aggregation alongside glycemic and lipid changes in 12 elderly subjects, raising an unquantified additive bleeding-tendency question that no study has followed up. Effect size and clinical relevance are unknown.

    PMID 28976155 (reduced platelet activity, n=12, open-label)

  • Pancreatic enzyme replacement therapy (pancrelipase)

    NeutralLow

    No pharmacokinetic or clinical interaction is documented; the practical concern is substitution rather than interaction, since Suprefort has no evidence of replacing enzyme therapy in exocrine pancreatic insufficiency.

    No interaction data identified; pancrelipase prescribing information for the standard of care

Known risks(2)

  • Allergic reaction to bovine pancreas-derived peptides

    Low

    No adverse events reported in clinical studies.

  • Potential interaction with diabetes medications

    Moderate

    If Suprefort affects glucose metabolism, it could theoretically interact with insulin or oral hypoglycemics. Diabetic patients should monitor blood glucose closely and consult their physician.

Drug interactions(2)

  • Insulin and oral hypoglycemics

    Theoretical interaction via glucose metabolism modulation; monitor blood glucose

  • Pancreatic enzyme supplements (pancrelipase)

    May have complementary effects; no documented interaction

Research & benefits

Evidence base

Evidence Level
Very Limited Evidence
Total Studies
2
Human Studies
59

One formal clinical study from the Khavinson Institute tested Suprefort in 34 patients over 15 days. Results were modest but positive for both pancreatitis and diabetes subgroups. The study was open-label, single-center, and small. No independent replication exists.

Researched for(3)

Rated by confidence in the evidence

  • Improved digestive function in chronic pancreatitis

    Low

    A small 12-patient Khavinson Institute trial found modest enzyme gains; not peer-reviewed or independently confirmed.

    Khavinson VV, St. Petersburg Institute of Bioregulation and Gerontology, clinical study report on Suprefort (12 chronic-pancreatitis patients vs. 8 controls, ~2003-2004); not published in a PubMed-indexed peer-reviewed journal. PMID 26519279 is unrelated (tested melatonin/epithalon, not this peptide) and should be dropped from this citation.

  • Glucose level stabilization in latent type 2 diabetes

    Low

    A small, unpublished institute study found glucose improvement in latent type 2 diabetics taking Suprefort.

    St. Petersburg Institute of Bioregulation and Gerontology open-label study (Khavinson group, Nov 2003-Jan 2004; 22 latent T2DM patients on Suprefort vs 17 matched controls); no PMID, not peer-reviewed. Indexed studies of KEDW, the synthetic tetrapeptide sold as Pancragen/pankragen-forte, concern a related but distinct product and do not apply to Suprefort.

  • Normalization of pancreatic exocrine and endocrine function

    Low

    One small open-label Khavinson trial found eased pancreatitis symptoms and a glucose-trend improvement.

    Khavinson Institute open-label clinical study of Suprefort itself, n=34 (12 chronic pancreatitis, 22 type 2 diabetes), matched controls, 15 days, Nov 2003-Jan 2004; not PubMed-indexed, no PMID available. Indexed studies of Pancragen, the synthesized single tetrapeptide KEDW isolated from the same pancreatic extract, concern a different, related compound and do not apply to Suprefort.

Benefits(3)

  • Improved digestive function in chronic pancreatitis

    Khavinson Institute clinical study (12 pancreatitis patients)

  • Glucose level stabilization in latent type 2 diabetes

    Khavinson Institute clinical study (22 diabetes patients)

  • Normalization of pancreatic exocrine and endocrine function

    Khavinson Institute preclinical and clinical data

Key studies(1)

  1. Clinical study of peptide bioregulator Suprefort

    Open-label clinical studyn=34 treatment + matched controls15 days

    Khavinson VKh et al.

    St. Petersburg Institute of Bioregulation and Gerontology (internal report)

    2011

    Pancreatitis patients showed improved appetite and reduced dyspepsia. Diabetes patients showed glucose stabilization. No adverse events reported.

Regulation & availability

Why researchers look at it

Suprefort targets pancreatic function with organ-specific peptides from young calf pancreas. It addresses both digestive enzyme production and glucose metabolism, two key aspects of metabolic aging that decline with age.

Estimated cost
$30-60/mo (capsules)
FDA status
Not FDA-approved; not reviewed by FDA; sold as dietary supplement internationally
WADA status
Not individually named on the WADA 2026 Prohibited List. S0 can prohibit unapproved pharmacological substances at all times; supplement registration does not establish therapeutic approval. Product-specific anti-doping status requires confirmation.
Prescribability
Available in Russia as dietary supplement; not approved in USA/EU
Availability
Not available through conventional pharmacies in USA/EU.

International status

  • EU

    Not approved

  • US

    Not approved

  • Russia

    Used clinically (Khavinson bioregulator protocol)

  • Worldwide

    Limited to Russian clinical use

Regulatory timeline(2)

  1. 2003-2004
    Clinical study conducted at St. Petersburg Institute (Nov 2003 - Jan 2004)
  2. 2000s
    Commercialized as Cytomaxes dietary supplement in Russia

Sources & FAQs

Research sources(1)

Frequently asked questions(3)

Can Suprefort help with diabetes?

A small Russian study showed glucose stabilization trends in patients with latent type 2 diabetes. However, this is not sufficient evidence to recommend Suprefort as a diabetes treatment. It should not replace prescribed diabetes medications.

What is the difference between Suprefort and Pancragen?

Suprefort is a natural peptide complex (Cytomaxes) extracted from animal pancreas, while Pancragen is a synthetic peptide (Cytogen) synthesized from amino acids. Both target the pancreas but through different production methods.

Are there any side effects?

No adverse events were reported in the Khavinson Institute clinical study. As a dietary supplement, it has not undergone the safety testing required for drug approval.